Abstract 2018P
Background
Small cell lung cancer (SCLC) is highly invasive and has a low 5-year survival rate. Programmed death receptor 1/programmed death receptor-ligand 1 (PD-L1) inhibitors have improved survival in SCLC patients partially, but more targets and precise beneficiary populations are needed. Delta-like ligand 3 (DLL3)-targeted drug Rova-T was terminated due to insufficient efficacy, considering other factors that may affect efficacy. This study aims to construct a prognostic model for SCLC patients based on the expression of DLL3 and PD-L1 to help determine prognosis and guide clinical therapy.
Methods
Immunohistochemistry was used to detect the expression of DLL3 and PD-L1 in the tissue specimens of SCLC patients. Independent risk factors were identified by Cox proportional risk regression to construct the model. The model was validated by consistency index (C-index), bootstrap resampling, and decision curve analysis (DCA).
Results
Up to March 15, 2023, 141 patients diagnosed with SCLC by pathology at Changzhi People's Hospital were included, and 129 patients have reached the endpoint. The expression rates of DLL3 and PD-L1 were 62.4% (88/141), 10.6% (15/141). NSE, stage, treatment, DLL3 and PD-L1 were independent risk factors for OS in SCLC patients (p<0.05). Based on these factors, a prediction model for the 12-month survival probability of SCLC patients was constructed and a nomogram was plotted. The model was tested for good discrimination (C-index 0.739), accuracy and clinical applicability. In addition, patients were divided into low-risk and high-risk for survival analysis based on the best cut-off value of 49.11 for nomogram, indicating that the model had great discrimination ability (mOS 13.33 vs. 7.80m, p<0.001).
Table: 2018P
Variable | Point | Overall point | 12-m survival probability | |
NSE per 50mg/ml | 6.16 | 0 | 0.78 | |
Stage | Limited | 0 | 10 | 0.72 |
Extensive | 20.47 | 20 | 0.65 | |
Treatment | Yes | 0 | 30 | 0.57 |
No | 100 | 40 | 0.47 | |
DLL3 | Negative | 0 | 50 | 0.37 |
Positive | 24.69 | 60 | 0.27 | |
PD-L1 | Negative | 0 | 70 | 0.17 |
Positive | 44.50 | 80 | <0.10 |
Conclusions
The OS prediction model for SCLC patients in this study has excellent predictive performance in predicting the 12-m survival probability and may assist clinicians in making more accurate judgments and guiding therapy of SCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1604P - A comparative study of symptom prevalence between adults and elderly patients with advanced cancer diagnosis under palliative care: A single institution experience
Presenter: Hodan Abdullah
Session: Poster session 05
1605P - The impact of cancer pain on survival of lung cancer patients receiving immune checkpoint inhibitors
Presenter: Sichao Wang
Session: Poster session 05
1606P - Sarcopenia, depression, and modes of feeding among cancer patients
Presenter: Muhammad Khokhar
Session: Poster session 05
1607P - Patient perceptions of the efficacy, safety, and quality of the evidence available on medicinal cannabis: A survey of Australian cancer patients - comparing users to non-users
Presenter: Joseph Taylor
Session: Poster session 05
1608P - Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy
Presenter: Omer Dizdar
Session: Poster session 05
1609P - A machine learning-based prognostic model to predict survival in patients with advanced cancer admitted to an acute palliative care unit
Presenter: Eun Hee Jung
Session: Poster session 05
1610P - A new updated prognostic index for patients with brain metastases (BM) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology: METASNCore project
Presenter: Pablo Flores Paco
Session: Poster session 05
1611P - Family carers’ experiences with brain metastases: A longitudinal qualitative study
Presenter: Tonje Lundeby
Session: Poster session 05
1612P - Demonstrating the complexity of need and the effectiveness of integrated palliative care: An analysis of routinely collected patient centred outcome measures
Presenter: Joanne Hayes
Session: Poster session 05
1613P - The BreakThrough cancer malnutrition
Presenter: Stefano De Santis
Session: Poster session 05